EP Patent

EP3983086A1 — Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Assigned to Bristol Myers Squibb Co · Expires 2022-04-20 · 4y expired

What this patent protects

Disclosed are crystalline salt Forms C and D of 6- (cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4- triazol-3-yl)phenyl)amino)-N-(methyl-d 3 )pyridazine-3-carboxamide. Form C is a MSA salt and Form D is a sulfate salt of Compound (I). Characterization data for the Fo…

USPTO Abstract

Disclosed are crystalline salt Forms C and D of 6- (cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4- triazol-3-yl)phenyl)amino)-N-(methyl-d 3 )pyridazine-3-carboxamide. Form C is a MSA salt and Form D is a sulfate salt of Compound (I). Characterization data for the Forms are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3983086A1
Jurisdiction
EP
Classification
—
Expires
2022-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.